Key result
Potassium channel modulators offer key therapeutic targets across arrhythmias, hypertension, and coronary heart disease.
Answers are grounded in this paper and cite their sources.
Potassium channels serve as diverse pharmacological targets in cardiovascular medicine, with blockers acting as antiarrhythmics and openers showing potential for cytoprotection during ischemia.
Potassium channels are membrane receptor sites for various drugs in the field of cardiovascular diseases. These channel proteins are extremely diverse, not only as regards their molecular structure but also as regards their function. Heterogeneous expression of various K+ channel subtypes is an integral part of cell specialization in different tissues. K+ channels interfere with most of the physiological processes of the cardiac muscle, of the vascular smooth muscle and of the endothelial cells. K+ channel blockers are antidiabetic agents but also antiarrhythmic drugs. K+ channel openers are used in the treatment of hypertension and most recently in the treatment of coronary heart disease. In the experimental setting, K+ channel openers afford cytoprotection during ischaemia. This exciting property opens a new field in clinical research.
No takes yet. Share an insight, caveat, or question.
Escande et al. (1993) conducted a review in Cardiovascular diseases. Potassium channel modulators was evaluated. Potassium channel modulators, including blockers and openers, serve as important pharmacological targets for treating cardiovascular diseases such as arrhythmias, hypertension, and coronary heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: